Elite Laboratories, Inc.: FDA regulatory profile

Elite Laboratories, Inc. appears in 2 indexed U.S. FDA records: 2 drug-shortage entries (from 10 openFDA source rows), naming 2 distinct products. Latest dated event: a shortage record dated 2026-08-20. Observations run 2022-10-12 to 2026-08-20 — 1408 days, 4 dated records across 3 calendar years, busiest 2026 with 2. Shortages: 2 current, averaging 5 package lines each across 1 FDA therapeutic category, 10 strengths, 134 package NDCs and 3 brand names. 6 related firms and 1 adjacent shortage entry are linked below, each by a shared shortage entry, substance or therapeutic category. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. By year: 2026 (2), 2023 (1), 2022 (1). Shortage entries include Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Current, since 2022-10-12, 6 lines) and Lisdexamfetamine Dimesylate Capsule (Current, since 2023-07-14, 4 lines). This firm appears in 2 indexed records, which is below the threshold this site requires before treating a manufacturer page as a standalone regulatory profile (only 2 indexed record). The page is published so the record remains reachable and verifiable, and it links on to the underlying FDA records, but it is marked noindex and left out of the sitemap: a single appearance of a company name is not a regulatory history, and presenting it as one would overstate what the data supports. Should further records reference this firm in a later ingestion, the page becomes a full profile automatically.